Richard Maroun Buys Shares of Whitehawk Therapeutics, Inc.

Richard Maroun acquired 38,040 shares of Whitehawk Therapeutics, Inc. on June 12, reflecting insider confidence.

Written by EarningsIQ · Published Jun 16, 2026, 2:04 AM EDT · Updated Jun 16, 2026, 9:01 AM EDT

Key Points

Richard Maroun purchased 38,040 shares of Whitehawk Therapeutics, Inc. on June 12, 2026.
Whitehawk Therapeutics, Inc. trades on the NasdaqCM under the ticker WHWK with a market cap of $202.8 million.
Analysts have given Whitehawk Therapeutics a 'buy' rating with a mean price target of $6.50.

Richard Maroun, an insider at Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK), purchased 38,040 shares of the company on June 12, 2026. This transaction adds to the recent insider buying activity, signaling potential confidence in the company's trajectory.

Other Institutional Activity in Whitehawk Therapeutics

Several institutional investors have maintained their positions in Whitehawk Therapeutics. QVT Financial LP holds 4,615,709 shares valued at approximately $15.9 million. Similarly, Orbimed Advisors LLC has 4,166,000 shares worth about $14.4 million. Suvretta Capital Management, LLC owns 3,700,000 shares with a value of $12.8 million. Acuta Capital Partners, LLC has 3,410,402 shares valued at $11.8 million, and Avoro Capital Advisors LLC holds 2,849,402 shares worth $9.8 million.

Whitehawk Therapeutics, Inc. Stock Snapshot

Shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK) recently traded around $4.16. The company has a market cap of approximately $202.8 million. Whitehawk Therapeutics shows a 52-week low of $1.57 and a high of $5.50, with a 50-day moving average of $4.15 and a 200-day moving average of $2.98. The firm has a high current ratio of 11.36, indicating strong liquidity.

Analysts Set New Price Targets

On April 16, 2026, Citizens initiated coverage on Whitehawk Therapeutics with a 'buy' rating and an $8.00 price target. Earlier, on December 22, 2025, Jones Trading also started coverage with a 'buy' rating, setting a target price of $7.00. The consensus among analysts is a 'buy' rating, with a mean price target of $6.50 based on four opinions.

About Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics, Inc., headquartered in Morristown, New Jersey, is a clinical-stage biotechnology company focused on developing oncology therapies. The company specializes in creating next-generation antibody-drug conjugates (ADCs) aimed at treating various cancers. It was formerly known as Aadi Bioscience, Inc. before rebranding in August 2021. Led by CEO Dr. David J. Lennon, the company employs 29 people.

Bottom Line

Richard Maroun's recent purchase of 38,040 shares in Whitehawk Therapeutics, Inc. highlights insider confidence in the company's future. Investors often track such insider activities as they can hint at potential growth or strategic changes. With a 'buy' consensus from analysts, Whitehawk Therapeutics remains a company to watch in the biotechnology sector.